Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain
Katrina Weston‐Green, Xu‐Feng Huang, Chao Deng
PLoS ONE (2012) Vol. 7, Iss. 3, pp. e33548-e33548
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Peter Manu, Lorena Dima, Matisyahu Shulman, et al.
Acta Psychiatrica Scandinavica (2015) Vol. 132, Iss. 2, pp. 97-108
Closed Access | Times Cited: 253
Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
Chao Deng
Endocrinology and Metabolism Clinics of North America (2013) Vol. 42, Iss. 3, pp. 545-563
Closed Access | Times Cited: 148
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, et al.
Neuropsychopharmacology (2017) Vol. 42, Iss. 7, pp. 1447-1457
Open Access | Times Cited: 131
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Spyridon Siafis, Dimitrios Tzachanis, Myrto Samara, et al.
Current Neuropharmacology (2017) Vol. 16, Iss. 8, pp. 1210-1223
Open Access | Times Cited: 130
Melatonin attenuates antipsychotic metabolic effects: an eight‐week randomized, double‐blind, parallel‐group, placebo‐controlled clinical trial
Francisco Romo‐Nava, Dení Alvarez‐Icaza González, Ana Fresán, et al.
Bipolar Disorders (2014) Vol. 16, Iss. 4, pp. 410-421
Closed Access | Times Cited: 109
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia
Mohini Ranganathan, Jose Cortes-Briones, Rajiv Radhakrishnan, et al.
Biological Psychiatry (2015) Vol. 79, Iss. 12, pp. 997-1005
Open Access | Times Cited: 106
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis
Pauline Vercruysse, Jérôme Sinniger, Hajer El Oussini, et al.
Brain (2016) Vol. 139, Iss. 4, pp. 1106-1122
Open Access | Times Cited: 89
The Novel Perspectives of Adipokines on Brain Health
Thomas H. Lee, Kenneth K.Y. Cheng, Ruby L.C. Hoo, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 22, pp. 5638-5638
Open Access | Times Cited: 81
Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes
Jiezhong Chen, Xu‐Feng Huang, Renfu Shao, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 77
Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives
Raghunath Singh, Yashika Bansal, Bikash Medhi, et al.
European Journal of Pharmacology (2018) Vol. 844, pp. 231-240
Closed Access | Times Cited: 69
Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
Jiamei Lian, Xu‐Feng Huang, Nagesh Pai, et al.
PLoS ONE (2014) Vol. 9, Iss. 8, pp. e104160-e104160
Open Access | Times Cited: 67
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
Simona Cernea, Lorena Dima, Christoph U. Correll, et al.
Drugs (2020) Vol. 80, Iss. 17, pp. 1763-1781
Closed Access | Times Cited: 54
A Focused Review of the Metabolic Side-Effects of Clozapine
Jessica W. Y. Yuen, David D. Kim, Ric M. Procyshyn, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 54
Understanding the Effects of Antipsychotics on Appetite Control
Sayani Mukherjee, Silje Skrede, Edward Milbank, et al.
Frontiers in Nutrition (2022) Vol. 8
Open Access | Times Cited: 35
Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways
Jiamei Lian, Xu‐Feng Huang, Nagesh Pai, et al.
Psychoneuroendocrinology (2014) Vol. 48, pp. 77-86
Closed Access | Times Cited: 60
Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism
M Koch, Tamas L. Horváth
Molecular Psychiatry (2014) Vol. 19, Iss. 7, pp. 752-761
Open Access | Times Cited: 53
Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats
Qingsheng Zhang, Meng Xiao He, Chao Deng, et al.
The International Journal of Neuropsychopharmacology (2014) Vol. 17, Iss. 05, pp. 807-818
Open Access | Times Cited: 53
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications
Jiamei Lian, Xu‐Feng Huang, Nagesh Pai, et al.
Pharmacological Research (2016) Vol. 106, pp. 51-63
Closed Access | Times Cited: 53
Management of nightmares in patients with posttraumatic stress disorder: current perspectives
Ali El-Solh
Nature and Science of Sleep (2018) Vol. Volume 10, pp. 409-420
Open Access | Times Cited: 51
Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia
Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 95, pp. 109666-109666
Closed Access | Times Cited: 51
Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders
Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, et al.
Brain Behavior and Immunity (2019) Vol. 81, pp. 574-587
Closed Access | Times Cited: 47
The role of ghrelin signalling in second-generation antipsychotic-induced weight gain
Qingsheng Zhang, Chao Deng, Xu‐Feng Huang
Psychoneuroendocrinology (2013) Vol. 38, Iss. 11, pp. 2423-2438
Closed Access | Times Cited: 54
Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs
Robin Schmidt, Jenny D. Jokinen, Veronica Massey, et al.
Journal of Pharmacology and Experimental Therapeutics (2013) Vol. 347, Iss. 1, pp. 126-135
Open Access | Times Cited: 54
Sex differences in cannabinoid-regulated biology: A focus on energy homeostasis
Edward J. Wagner
Frontiers in Neuroendocrinology (2016) Vol. 40, pp. 101-109
Open Access | Times Cited: 46
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats
Paolo Lazzari, Valeria Serra, S. Marcello, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 7, pp. 667-678
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top